Radioembolisation mit Harz- und Glas-Mikrosphären DOI
Harun Ilhan, Lars Stegger, Hojjat Ahmadzadehfar

и другие.

Angewandte Nuklearmedizin, Год журнала: 2023, Номер 46(04), С. 281 - 306

Опубликована: Дек. 1, 2023

Die transarterielle Radioembolisation (TARE) ist eine lokal ablative Therapieoption bei primären und sekundären Lebertumoren mit leberdominanter Erkrankung. Dieser Artikel gibt einen Überblick über die gängigsten Indikationen, Patientenselektion, Therapieplanung -durchführung sowie Nachsorge der Patienten. Der Fokus liegt auf Yttrium-90-beladenen Glas- Harzmikrosphären, wobei weite Teile dieser Übersicht auch für Holmium-166 beladene Mikrosphären gelten.

Latest advances in hepatocellular carcinoma management and prevention through advanced technologies DOI Creative Commons

Tamer A. Addissouky,

Ibrahim El Tantawy El Sayed, Majeed M. A. Ali

и другие.

Egyptian Liver Journal, Год журнала: 2024, Номер 14(1)

Опубликована: Янв. 2, 2024

Abstract Background Hepatocellular carcinoma (HCC) is a common type of liver cancer, with high mortality rate. cancer that can be effectively managed through early detection and accurate diagnosis, followed by personalized treatment plan may include surgical resection, transplantation, minimally-invasive techniques, immunotherapy, or targeted therapy depending on the stage severity cancer. Main body abstract This paper discusses recent advances in detection, management, prevention HCC. The use newer imaging such as Magnetic resonance (MRI) contrast-enhanced ultrasound, along image segmentation technology deep learning models, have greatly enhanced accuracy HCC diagnosis. Minimally-invasive thermal ablation radiofrequency ablation, allowed for more precise destruction tumors, while Nanoparticles, immunotherapy shown promise management advanced Artificial intelligence (AI) machine has revolutionized research, aiding identification high-risk patients predicting outcomes. Lifestyle modifications, weight alcohol avoidance, hepatitis B vaccinations, play critical role preventing development. Short conclusion Recent improving patient therapy, AI research lifestyle modifications prevention. However, further required to fully understand potential benefits nanoparticles, traditional Chinese medicine herbal medicines treatment. Graphical

Язык: Английский

Процитировано

35

Non-coding RNA mediated regulation of PI3K/Akt pathway in hepatocellular carcinoma: Therapeutic perspectives DOI
Md Sadique Hussain, Ehssan Moglad, Muhammad Afzal

и другие.

Pathology - Research and Practice, Год журнала: 2024, Номер 258, С. 155303 - 155303

Опубликована: Апрель 28, 2024

Язык: Английский

Процитировано

17

Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis DOI

Baofa Yu,

Wenxue Ma

Cytokine & Growth Factor Reviews, Год журнала: 2024, Номер 79, С. 29 - 38

Опубликована: Авг. 24, 2024

Язык: Английский

Процитировано

10

A multitask deep learning radiomics model for predicting the macrotrabecular-massive subtype and prognosis of hepatocellular carcinoma after hepatic arterial infusion chemotherapy DOI Creative Commons
Xuelei He, Kai Li, Ran Wei

и другие.

La radiologia medica, Год журнала: 2023, Номер 128(12), С. 1508 - 1520

Опубликована: Окт. 6, 2023

Abstract Background The macrotrabecular-massive (MTM) is a special subtype of hepatocellular carcinoma (HCC), which has commonly dismal prognosis. This study aimed to develop multitask deep learning radiomics (MDLR) model for predicting MTM and HCC patients’ prognosis after hepatic arterial infusion chemotherapy (HAIC). Methods From June 2018 March 2020, 158 eligible patients with who underwent surgery were retrospectively enrolled in related cohorts, 752 HAIC included cohorts during the same period. DLR features extracted from dual-phase (arterial phase venous phase) contrast-enhanced computed tomography (CECT) entire liver region. Then, an MDLR was used simultaneous prediction patient HAIC. prognostic risk stratification incorporated signatures, clinical variables subtype. Findings predictive performance 0.968 training cohort [TC], 0.912 internal test [ITC] 0.773 external [ETC], respectively. Multivariable analysis identified portal vein tumor thrombus (PVTT) ( p = 0.012), response < 0.001), sessions 0.001) as indicators poor After incorporating yielded best among all models (AUC, 0.855 TC, 0.805 ITC 0.792 ETC). With these variables, provided two strata overall survival (OS) TC: low (5-year OS, 44.9%) high 4.9%). Interpretation A tool based on developed consider that important factor patients. showed outstanding may help physicians therapeutic decision making surveillance strategy selection practice.

Язык: Английский

Процитировано

17

New 2,4-diaryl-3-azabicyclo[3.3.1]nonan-9-one derivatives as antimicrobial and anti-cancer agents: Synthesis, in-vitro and SAR studies DOI
Farid M. Sroor, Abdelmageed M. Othman, Khaled Mahmoud

и другие.

Journal of Molecular Structure, Год журнала: 2023, Номер 1294, С. 136516 - 136516

Опубликована: Авг. 30, 2023

Язык: Английский

Процитировано

14

Realizing the Promise of Artificial Intelligence in Hepatocellular Carcinoma through Opportunities and Recommendations for Responsible Translation DOI Creative Commons

Tamer A. Addissouky,

Majeed M. A. Ali,

Ibrahim El Tantawy El Sayed

и другие.

Jurnal Online Informatika, Год журнала: 2024, Номер 9(1), С. 70 - 79

Опубликована: Апрель 26, 2024

This study aims to provide an overview of the current state-of-the-art applications artificial intelligence (AI) and machine learning in management hepatocellular carcinoma (HCC), explore future directions for continued progress this emerging field. is a comprehensive literature review that synthesizes recent findings advancements application AI techniques across various aspects HCC care, including screening early detection, diagnosis staging, prognostic modeling, treatment planning, interventional guidance, monitoring response. The draws upon wide range published research studies, focusing on integration with diverse data sources, such as medical imaging, clinical data, genomics, other multimodal information. results demonstrate AI-based systems have shown promise improving accuracy efficiency screening, diagnosis, tumor characterization compared traditional methods. Machine models integrating clinical, genomic outperformed conventional staging predicting survival recurrence risk. recommendation potential optimize personalized therapy selection, while augmented reality can guide procedures real-time. Moreover, longitudinal may enhance assessment response monitoring. Despite these promising findings, highlights need rigorous multicenter prospective validation standardized datasets, thoughtful consideration ethical implications before widespread implementation technologies management.

Язык: Английский

Процитировано

5

Unlocking the potential of gold nanoparticles as a game-changer in the fight against hepatocellular carcinoma DOI Creative Commons
Sarmistha Saha, Manish Taneja, S. Dubey

и другие.

Exploration of Medicine, Год журнала: 2025, Номер unknown

Опубликована: Янв. 13, 2025

According to research, hepatocellular carcinoma (HCC), ranks third globally in terms of cause death and is the fifth most common type cancer overall. Finding novel means diagnosis treatment therefore crucial. The use nanotechnology as a has drawn lot interest recently. Despite significant advancements detection treatment, there still long way go before this disease completely eradicated. Therefore, it’s critical find innovative ways diagnose cure conditions. In particular, substantial inertness metallic nanoparticles (NPs) their nanoscale structures, which have sizes comparable many biological molecules, attract great deal biomedical field. Due exceptional optical qualities, chemically modified surface through attachment various ligands, biocompatibility (bio-inertness low cytotoxicity), superior properties, gold NPs (AuNPs) garnered interest. current review discusses efficiency AuNPs fields, including imaging, immunotherapy, photothermal therapy for treating liver cancer. Finally, summarized limitations prospects AuNPs.

Язык: Английский

Процитировано

0

Integrating artificial intelligence into multidisciplinary evaluations of HCC: opportunities and challenges DOI Open Access
Walaa Abdelhamed, Mohamed El‐Kassas

Hepatoma Research, Год журнала: 2025, Номер unknown

Опубликована: Март 4, 2025

Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer and a leading cause of cancer-related mortality globally. The heterogeneity HCC complicates prognostic, management, predictive strategies across different patient populations. Recent advancements in artificial intelligence (AI) machine learning (ML) offer transformative opportunities to improve management. This review consolidates findings from various studies regarding integrating AI detecting, diagnosing, treating HCC, leveraging diverse data sources such as radiological imaging, genomics, clinical records. AI-based approaches have shown potential accuracy efficiency screening, early detection, tumor characterization, treatment response evaluation, surpassing traditional methods. However, deployment technologies hindered by challenges, including standardization, validation multiple centers, ethical considerations applications. emphasizes need establish comprehensive multimodal datasets collaborative research efforts validate applications By addressing these integration technology has revolutionize care, ultimately improved outcomes more personalized approach strategies.

Язык: Английский

Процитировано

0

Toolbox for creating three-dimensional liver models DOI
Irina Panchuk, Svetlana Smirnikhina

Biochemical and Biophysical Research Communications, Год журнала: 2024, Номер 731, С. 150375 - 150375

Опубликована: Июль 9, 2024

Язык: Английский

Процитировано

3

Advancing Cancer Therapy: A Review of Recent Progress in Monoclonal Antibodies DOI Creative Commons

Buddadasari Snehitha,

Mopuri Jyothsna,

A Sai

и другие.

Asian Journal of Advances in Research, Год журнала: 2024, Номер 7(1), С. 159 - 173

Опубликована: Апрель 24, 2024

A new era in cancer treatment has begun with the development of monoclonal antibodies (mAbs), which have improved therapeutic results and precision targeting to a great extent. Specialized (mAbs) are engineered attach specifically antigens, allowing them directly target tumor cells influence immune system for purposes. Significant advancements this field include approval clinical efficacy mAbs that B-cell lymphomas HER2-positive breast cancer. Notable cases like as trastuzumab rituximab highlight real benefits these treatments, better patient outcomes survival rates. Furthermore, by triggering body's immunological defenses against cells, checkpoint inhibitors pembrolizumab completely changed way is treated. For individuals previously difficult-to-treat illnesses, innovative technique shown extraordinary success across variety types. Innovative approaches including antibody-drug conjugates bispecific also been produced ongoing developments mAb engineering. These technical miracles improve overall safety profile (mAb) therapeutics compensating off-target effects optimizing efficacy. There still issues, such toxicity emergence drug resistance, spite significant progress. Even Nevertheless, continued research initiatives enormous potential customized plans. advances promise future patients everywhere highlighting quick evolution therapies encouraging increased innovation vital area medicine.

Язык: Английский

Процитировано

1